Hypertriglyceridemia Pipeline Insight, 2020 By DelveInsight

 Breaking News
  • No posts were found

Hypertriglyceridemia Pipeline Insight, 2020 By DelveInsight

August 12
12:26 2020
Hypertriglyceridemia Pipeline Insight, 2020 By DelveInsight


(Albany, US) DelveInsight has launched a new report Hypertriglyceridemia Pipeline

Hypertriglyceridemia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hypertriglyceridemia market. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided, which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces in-depth Hypertriglyceridemia commercial assessment and clinical assessment of the Hypertriglyceridemia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Hypertriglyceridemia refers to a fasting plasma triglyceride measurement that is increased, typically above the 95th percentile for age and sex along with additional quantitative or qualitative lipoprotein abnormalities. Patients can fluctuate between hypertriglyceridemia states: given appropriate metabolic stress, mild or moderate hypertriglyceridemia can deteriorate into severe hypertriglyceridemia. The two main sources of plasma triglycerides (also known as triacylglycerol) are exogenous (i.e., from dietary fat)—carried in chylomicrons, and endogenous (from the liver)—carried in very-low-density lipoprotein (VLDL) particles.


Request for free sample page:- https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight


Hypertriglyceridemia Pipeline Development activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Hypertriglyceridemia with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Hypertriglyceridemia treatment.
  • Hypertriglyceridemia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Hypertriglyceridemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc. 


Hypertriglyceridemia Pipeline

The dynamics of Hypertriglyceridemia (HTG) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period. Companies across the globe are thoroughly working towards the development of new treatment therapies for hypertriglyceridemia (HTG). Some of the key players in the therapeutic market of hypertriglyceridemia (HTG) at a global level are Regeneron Pharmaceuticals, Acasti Pharma, Arrowhead Pharmaceuticals and others. While some of the companies have recently shifted their focus towards this indication, yet others are expected to create a significant influence on the market size during the forecast period.

Some of the products which are currently in late and mid-stage clinical development include Regeneron Pharmaceuticals’ Evinacumab, and Acasti Pharma’s CaPre, K-877 of Kowa Research Institute, Inc. (a division of Kowa Co., Ltd.) and several others. Acasti Pharma’s CaPre, the company’s lead drug candidate, is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are present as a combination of phospholipid esters and free fatty acids. It is in Phase III stage of development for the treatment of hypertriglyceridemia and recently announced that despite positive results in CaPre arm, the study did not reach statistical significance due to unusually large placebo effect; further analysis is underway. Acasti’s growing global patent portfolio encompasses CaPre and its composition until the last of its patents expire in 2031. Acasti currently holds numerous composition of matter and method of use patents in various jurisdictions around the world including in the US, China, Japan, Taiwan and Australia, and have numerous additional patents pending. Regeneron Pharmaceuticals’ Evinacumab (also known as REGN1500), an intravenous ANGPTL-3 Antibody is under Phase II stage of development for the treatment of Refractory hypercholesterolemia (both HeFH and non-FH) and hypertriglyceridemia. It is the company’s most clinically advanced rare disease antibody. Currently, the company is conducting a Phase II trial for safety and efficacy following repeat-dose of Evinacumab (Anti-ANGPTL3) in patients with hypertriglyceridemia (HTG) at risk for Acute Pancreatitis. Arrowhead pharmaceutical’s ARO-APOC3 is designed to reduce the production of Apolipoprotein C-III (apoC-III), a component of triglyceride-rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. Data from phase I study demonstrated that, in single-dose clinical studies in healthy volunteers, ARO-APOC3 reduced plasma Apolipoprotein C-III (apoC-III) and reduced triglycerides without drug-related serious or severe adverse events.


Marketed Drugs included in the report

  • Epanova (omega-3-carboxylic acids): AstraZeneca
  • Vascepa: Amarin Pharma Inc.
  • Lovaza (omega-3-acid ethyl esters): GlaxoSmithKline


Emerging drugs included in the report

  • Evinacumab: Regeneron Pharmaceuticals
  • CaPre: Acasti Pharma
  • K-877: Kowa Research Institute, Inc. (a division of Kowa Co., Ltd.)


Hypertriglyceridemia Report Scope

  • The Hypertriglyceridemia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Hypertriglyceridemia across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Hypertriglyceridemia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Hypertriglyceridemia research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hypertriglyceridemia.


Request for free sample page:- https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight


Table of content

1. Report Introduction

2. Hypertriglyceridemia 

3. Hypertriglyceridemia Current Treatment Patterns

4. Hypertriglyceridemia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hypertriglyceridemia Late Stage Products (Phase-III)

7. Hypertriglyceridemia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hypertriglyceridemia Discontinued Products

13. Hypertriglyceridemia Product Profiles

14. Hypertriglyceridemia Key Companies

15. Hypertriglyceridemia Key Products

16. Dormant and Discontinued Products

17. Hypertriglyceridemia Unmet Needs

18. Hypertriglyceridemia Future Perspectives

19. Hypertriglyceridemia Analyst Review  

20. Appendix

21. Report Methodology

22. About DelveInsight 


Related Reports



About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.



Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/